DE60111568T2 - Tetrahydro-(benzo- oder thieno-)azepin-pyrazin und triazinderivative als mglur 1 antagonisten - Google Patents

Tetrahydro-(benzo- oder thieno-)azepin-pyrazin und triazinderivative als mglur 1 antagonisten Download PDF

Info

Publication number
DE60111568T2
DE60111568T2 DE60111568T DE60111568T DE60111568T2 DE 60111568 T2 DE60111568 T2 DE 60111568T2 DE 60111568 T DE60111568 T DE 60111568T DE 60111568 T DE60111568 T DE 60111568T DE 60111568 T2 DE60111568 T2 DE 60111568T2
Authority
DE
Germany
Prior art keywords
formula
chr
compounds
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60111568T
Other languages
German (de)
English (en)
Other versions
DE60111568D1 (de
Inventor
Alfred Binggeli
Hans-Peter Maerki
Vincent Mutel
Maurice Wilhelm
Wolfgang Wostl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60111568D1 publication Critical patent/DE60111568D1/de
Publication of DE60111568T2 publication Critical patent/DE60111568T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE60111568T 2000-12-22 2001-12-11 Tetrahydro-(benzo- oder thieno-)azepin-pyrazin und triazinderivative als mglur 1 antagonisten Expired - Lifetime DE60111568T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00128329 2000-12-22
EP00128329 2000-12-22
PCT/EP2001/014527 WO2002051418A1 (en) 2000-12-22 2001-12-11 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists

Publications (2)

Publication Number Publication Date
DE60111568D1 DE60111568D1 (de) 2005-07-21
DE60111568T2 true DE60111568T2 (de) 2006-05-11

Family

ID=8170787

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60111568T Expired - Lifetime DE60111568T2 (de) 2000-12-22 2001-12-11 Tetrahydro-(benzo- oder thieno-)azepin-pyrazin und triazinderivative als mglur 1 antagonisten

Country Status (17)

Country Link
US (1) US6586422B2 (enExample)
EP (1) EP1345609B1 (enExample)
JP (1) JP4077319B2 (enExample)
KR (1) KR100545906B1 (enExample)
CN (1) CN1260226C (enExample)
AR (1) AR032379A1 (enExample)
AT (1) ATE297734T1 (enExample)
AU (1) AU2002216095B2 (enExample)
BR (1) BR0116378A (enExample)
CA (1) CA2432077C (enExample)
DE (1) DE60111568T2 (enExample)
DK (1) DK1345609T3 (enExample)
ES (1) ES2243400T3 (enExample)
MX (1) MXPA03005515A (enExample)
PT (1) PT1345609E (enExample)
WO (1) WO2002051418A1 (enExample)
ZA (1) ZA200304557B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1981337B1 (en) 2006-01-19 2015-09-02 Athersys, Inc. Thiophenyl azepines as serotonin 5-ht2c receptor ligands and uses thereof
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR101100864B1 (ko) * 2009-06-12 2012-01-02 양준호 자동차 광택기용 광택패드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3136654A1 (de) 1981-09-16 1983-03-31 Zahnradfabrik Friedrichshafen Ag, 7990 Friedrichshafen Linearverschieblicher arbeitsarm, insbesondere fuer handhabungsgeraete
AU2642699A (en) * 1998-03-03 1999-09-20 Yamanouchi Pharmaceutical Co., Ltd. Remedies for brain infarction
IL142047A0 (en) * 1998-10-02 2002-03-10 Sibia Neurosciences Inc Mglur5 antagonists for the treatment of pain and anxiety
GB9823847D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
ES2209728T3 (es) * 1999-08-06 2004-07-01 F. Hoffmann-La Roche Ag Tetrahidro-benzo(d)azepinas y su uso como antagonistas de receptores de glutamato metabotropico.
EP1074549B1 (en) * 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors

Also Published As

Publication number Publication date
KR100545906B1 (ko) 2006-01-26
CN1487831A (zh) 2004-04-07
JP4077319B2 (ja) 2008-04-16
CN1260226C (zh) 2006-06-21
ATE297734T1 (de) 2005-07-15
US20020123488A1 (en) 2002-09-05
KR20030062444A (ko) 2003-07-25
PT1345609E (pt) 2005-08-31
AR032379A1 (es) 2003-11-05
DK1345609T3 (da) 2005-10-03
US6586422B2 (en) 2003-07-01
DE60111568D1 (de) 2005-07-21
JP2004517850A (ja) 2004-06-17
ES2243400T3 (es) 2005-12-01
AU2002216095B2 (en) 2005-12-01
MXPA03005515A (es) 2003-09-25
CA2432077A1 (en) 2002-07-04
BR0116378A (pt) 2003-10-28
WO2002051418A1 (en) 2002-07-04
CA2432077C (en) 2011-01-18
EP1345609B1 (en) 2005-06-15
ZA200304557B (en) 2004-09-13
EP1345609A1 (en) 2003-09-24

Similar Documents

Publication Publication Date Title
DE60108759T2 (de) Tetrahydro-heterocycloazepinyl-pyrimidin-derivate
DE60017376T2 (de) Carbaminsäurederivate und ihre verwendung als liganden von metabotropen glutamatrezeptoren
DE69826883T2 (de) Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren
DE602005004287T2 (de) Pyrrazolopyrimidinderivate
DE60129697T2 (de) Kondensierte azepinderivate und ihre verwendung als antidiuretisches mittel
DE60132235T2 (de) Tetrahydrobenzazepin-derivate zur verwendung als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)
DE60305484T2 (de) Verbindungen und deren verwendung als 5-ht inhibitoren
DE60111568T2 (de) Tetrahydro-(benzo- oder thieno-)azepin-pyrazin und triazinderivative als mglur 1 antagonisten
DD207716A5 (de) Verfahren zur herstellung von 1,2,4-triazinen und von pyrazinen
DD273833A5 (de) N 9 - cyclopentylsubstituierte adeninderivate
DE69732090T2 (de) Indol-2,3-dione-3-oxim derivate
DE602004009796T2 (de) Imidazolderivate als glutamatrezeptorantagonisten
DE69828284T2 (de) Naphthyridinderivate oder salze davon
DE10343098A1 (de) Tetrahydrochinoxaline und ihre Verwendung
DE69720021T2 (de) 1,4-disubstituierte piperazine
AU2002216095A1 (en) Tetrahydro-(Benzo or Thieno)-Azepine-Pyrazine and Triazine Derivatives as mGluR 1 Antagonists
DE69922936T2 (de) Verwendung von indol-2,3-dione-3-oximderivate als ampa-antagonisten
DE1695132A1 (de) Verfahren zur Herstellung von heterocyclischen Verbindungen
DD282457A5 (de) Verfahren zur herstellung neuer heterocyclischer derivate
DE69717449T2 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
DE60215804T2 (de) 4-aminopyrimidine derivate
DE602004012268T2 (de) Imidazol-Derivate und ihre Verwendung in der Behandlung von mGluR5-Rezeptor vermittelten Krankheiten
DE69413112T2 (de) 5-HT3 Pyrrolopyrazinderivate
DE602004000158T2 (de) Triazole für die Behandlung von auf die Modulation des Dopamin D3 Rezeptors ansprechende Krankheiten
DE68910593T2 (de) Chinolinoncarbonsäuren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition